COPENHAGEN, Denmark – November 5, 2021 - Bavarian Nordic A/S (OMX: BAVA) will announce its 2021 third quarter results on Friday, November 12, 2021.
View post:
Bavarian Nordic to Host Third Quarter 2021 Results Conference Call
Posted: November 8, 2021 at 2:33 am
COPENHAGEN, Denmark – November 5, 2021 - Bavarian Nordic A/S (OMX: BAVA) will announce its 2021 third quarter results on Friday, November 12, 2021.
View post:
Bavarian Nordic to Host Third Quarter 2021 Results Conference Call
Posted: November 8, 2021 at 2:33 am
NEW YORK, NY, Nov. 05, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire -- Tauriga Sciences, Inc. (OTCQB: TAUG) (“Tauriga” or the “Company”), a New York based diversified Life Sciences Company, has today reported continued strength and accelerating growth in its highest margin E-Commerce business segment (“E-Comm”). The Company generated strong monthly E-Comm sales for the recently completed month of October 2021. As of today’s date, November 5, 2021, the Company is firmly on track to generate record quarterly E-Comm sales – for its current operating quarter (October 1st– December 31st 2021).
Posted: November 8, 2021 at 2:33 am
Monthly information related to total number of voting rights and shares composing the share capital – October 30, 2021.
Posted: November 8, 2021 at 2:33 am
Eyenovia will release third quarter 2021 results on Wednesday, November 10, after the close. The prior version of this press release incorrectly stated that third quarter 2021 results would be released on Thursday, November 11, after the close.
Excerpt from:
CORRECTING AND REPLACING: Eyenovia to Report Third Quarter 2021 Results on Wednesday, November 10
Posted: November 8, 2021 at 2:33 am
Company conference call and webcast at 4:30 PM ET Company conference call and webcast at 4:30 PM ET
See the original post here:
TFF Pharmaceuticals to Hold Third Quarter 2021 Financial and Business Results Conference Call on November 15, 2021
Posted: November 8, 2021 at 2:33 am
BERKELEY, Calif. and MAINZ, Germany, Nov. 05, 2021 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ) (“Mainz Biomed” or the “Company”), a molecular genetics diagnostics company specializing in the early detection of cancer, today announced that its common stock commenced trading on the Nasdaq Capital Market today under the ticker symbol MYNZ. The shares closed above the offering price at $9.99.
See the original post here:
MYNZ Closes Its First Day of Trading on the Nasdaq Capital Market
Posted: November 8, 2021 at 2:33 am
NEW YORK, Nov. 05, 2021 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that it will participate in the following upcoming investor conferences in November:
Here is the original post:
atai Life Sciences to Participate in Upcoming November Investor Conferences
Posted: November 8, 2021 at 2:33 am
Bagsværd, Denmark, 5 November 2021 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
Read the original here:
Trading in Novo Nordisk shares by board members, executives and associated persons on 5 November 2021
Posted: November 8, 2021 at 2:33 am
NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS
Posted: November 8, 2021 at 2:33 am
SAN DIEGO, Nov. 07, 2021 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc. (Nasdaq: SRNE, "Sorrento") today announced that the California Competes Tax Credit Committee has approved the California Competes Tax Credit Allocation Agreement (the “Agreement”) between Sorrento and the California Governor’s Office of Business and Economic Development (“GO-Biz”). Pursuant to the Agreement, Sorrento has been awarded, subject to the satisfaction of certain milestones specified in the Agreement, an income tax credit from the State of California in an aggregate amount of up to $25,000,000. This incentivized credit is expected to support Sorrento’s vision of growth and expansion within the State of California.
Continued here:
Sorrento Awarded California Competes Tax Credit